Glaukos Corporation (GKOS)
Stock Price:
$41.75 USD
-1.70 (-3.91%)
Updated Aug 10, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
1.85B |
| Revenue (ttm) |
211.25M |
| Net Income (ttm) |
-37.29M |
| Shares Out |
44.18M |
| EPS (ttm) |
-1.72 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 10, 2020 |
| Last Price |
$41.75 |
| Previous Close |
$43.45 |
| Change ($) |
-1.70 |
| Change (%) |
-3.91% |
| Day's Open |
43.19 |
| Day's Range |
41.41 - 43.68 |
| Day's Volume |
595,821 |
| 52-Week Range |
23.31 - 76.06 |
More Stats
| Market Cap |
1.85B |
| Enterprise Value |
1.75B |
| Earnings Date (est) |
Nov 4, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
44.18M |
| Float |
43.17M |
| EPS (basic) |
-0.79 |
| EPS (diluted) |
-1.72 |
| FCF / Share |
-0.42 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
6.81M |
| Short Ratio |
10.72 |
| Short % of Float |
21.64% |
| Beta |
1.77 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
8.74 |
| PB Ratio |
3.00 |
| Revenue |
211.25M |
| Operating Income |
-100.96M |
| Net Income |
-37.29M |
| Free Cash Flow |
-18.53M |
| Net Cash |
100.12M |
| Net Cash / Share |
2.26 |
| Gross Margin |
95.81% |
| Operating Margin |
-47.79% |
| Profit Margin |
-15.60% |
| FCF Margin |
-8.77% |
| ROA |
-7.21% |
| ROE |
-16.67% |
| ROIC |
-32.80% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (11)
| Buy |
4 |
| Overweight |
0 |
| Hold |
4 |
| Underweight |
1 |
| Sell |
2 |
Analyst Consensus: Overweight
Price Target
$48.33*
(15.76% upside)
Low
43.0
Current: $41.75
High
60.0
Target: 48.33
*Average 12-month price target from 9 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|
| Revenue | 237 | 181 | 159 | 114 | 71.70 | 45.59 | 20.95 |
| Revenue Growth | 30.73% | 13.83% | 39.21% | 59.55% | 57.28% | 117.64% | - |
| Gross Profit | 198 | 156 | 138 | 98.22 | 58.71 | 34.17 | 18.41 |
| Operating Income | -50.29 | -13.00 | -2.28 | 4.24 | -10.30 | -13.17 | -14.20 |
| Net Income | 15.42 | -12.95 | -0.09 | 4.52 | -37.24 | -12.13 | -12.64 |
| Shares Outstanding | 37.36 | 35.32 | 34.38 | 32.93 | 17.47 | 2.29 | 2.04 |
| Earnings Per Share | 0.37 | -0.37 | - | 0.12 | -2.13 | -5.29 | -6.21 |
| Operating Cash Flow | -0.37 | 18.86 | 26.09 | 12.31 | -2.19 | -7.11 | -13.31 |
| Capital Expenditures | -4.72 | -10.32 | -6.31 | -6.28 | -0.88 | -0.87 | -0.85 |
| Free Cash Flow | -5.09 | 8.55 | 19.78 | 6.03 | -3.07 | -7.98 | -14.16 |
| Cash & Equivalents | 183 | 149 | 119 | 95.84 | 91.20 | 2.36 | 6.79 |
| Total Debt | 72.63 | - | - | - | 9.70 | 19.35 | 17.50 |
| Net Cash / Debt | 111 | 149 | 119 | 95.84 | 81.51 | -16.99 | -10.71 |
| Assets | 818 | 207 | 166 | 134 | 117 | 26.02 | 30.88 |
| Liabilities | 145 | 33.11 | 27.63 | 17.10 | 21.47 | 29.55 | 23.71 |
| Book Value | 673 | 174 | 138 | 117 | 95.19 | -151 | -141 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Glaukos Corporation |
| Country |
United States |
| Employees |
600 |
| CEO |
Thomas William Burns |
Stock Information
| Ticker Symbol |
GKOS |
| Stock Exchange |
New York Stock Exchange |
| Sector |
Healthcare |
| Industry |
Medical Instruments & Supplies |
| Unique Identifier |
NYSE: GKOS |
| IPO Date |
June 25, 2015 |
Description
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma; and iStent inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry for the reduction of intraocular pressure in mild-to-moderate open-angle glaucoma in combination with cataract surgery. The company's product pipeline includes iStent Infinite trabecular micro-bypass system, which is used as a standalone procedure in patients with refractory glaucoma; iStent Supra suprachoroidal micro-bypass stent that is designed to reduce intraocular pressure by accessing the suprachoroidal space in the eye; iStent SA trabecular micro-bypass system, a two-stent product, which uses a different auto-injection inserter designed for use in a standalone procedure; and iDose, a targeted injectable drug delivery implant that is designed to be pre-loaded into a small gauge needle and injected into the eye through a self-sealing corneal needle penetration. The company markets its products through direct sales force in the United States and other 16 countries, as well as through distribution partners in Europe, the Asia Pacific, Latin America, and internationally. Glaukos Corporation was founded in 1998 and is headquartered in San Clemente, California.